ABSTRACT
To assess objectively a dynamics of brain functional state, EEG spectral power and peak latency of the P300 component of cognitive auditory evoked potentials have been analyzed in adolescents during the course of nootropic therapy of residual asthenic consequences of traumatic brain injury (ICD-10 F07.2). The study included 76 adolescents, aged 12-18 years, who have undergone severe closed head trauma with brain commotion 1/2--5 years ago. Patients have been divided into 3 groups treated during one month with cerebrolysin, piracetam or magne-B6, respectively. After the end of the nootropic therapy, 77% of patients treated with cerebrolysin as well as 50% of patients treated with piracetam and magne-B6 have demonstrated the positive dynamics of their brain functional state that manifested itself in the appearance of occipital EEG alpha rhythm or in the increase of its spectral power; in the normalization of alpha rhythm frequency; in the decrease in the spectral power of slow wave (theta and delta) EEG activity, in the amount (up to the disappearance) of paroxysmal EEG activity, in the EEG response to hyperventilation and in the shortening of the P300 peak latency. Such positive changes of neurophysiological parameters have been associated with the improvement of clinical conditions of patients and correlated significantly with the dynamics of psychometric scores of attention and memory.
Subject(s)
Amino Acids/therapeutic use , Asthenia/prevention & control , Brain Injuries/drug therapy , Brain Injuries/physiopathology , Nootropic Agents/therapeutic use , Piracetam/therapeutic use , Adolescent , Asthenia/etiology , Brain Injuries/complications , Child , Electroencephalography , Female , Humans , Magnesium/therapeutic use , Male , Treatment Outcome , Vitamin B 6/therapeutic useABSTRACT
The efficacy of piracetam in treating the sequelae of moderate and severe closed craniocerebral trauma (CCT) in adolescents was evaluated in studies of 42 patients aged 12-18 years who had suffered CCT 1.5-5 years prior to the study. Adolescents of the experimental group (20 individuals) received piracetam (Nootropil) at doses of 40-50 mg/kg (daily daily 1600-2400 mg) for one month; patients of group 2 (22 individuals) served as controls. Piracetam was found to have positive therapeutic effects on impairments to higher mental (memory, attention, executive) and motor (coordination) functions and on measures of the speeds of cognitive and motor operations.
Subject(s)
Brain Injuries/drug therapy , Neuroprotective Agents/therapeutic use , Nootropic Agents/therapeutic use , Piracetam/therapeutic use , Adolescent , Age Factors , Attention/drug effects , Brain Injuries/physiopathology , Child , Female , Follow-Up Studies , Humans , Male , Memory/drug effects , Neuroprotective Agents/administration & dosage , Neuroprotective Agents/pharmacology , Nootropic Agents/administration & dosage , Nootropic Agents/pharmacology , Piracetam/administration & dosage , Piracetam/pharmacology , Psychomotor Performance/drug effects , Time FactorsABSTRACT
The efficacy of piracetam in the treatment of the consequences of moderate and severe closed traumatic brain injury was assessed in 42 patients, aged 12-18 years, who suffered traumatic disorders 1,5-5 years before this study. Adolescents from the main group (20 patients) received piracetam in dosage of 40-50 mg/kg (or 1600-2400 mg daily) during one month. 22 patients of the second group were examined as controls. The positive therapeutic effects of piracetam on cognitive (memory, attention, executive functions) and motor (coordination) functions as well as the speed of cognitive and motor performance were demonstrated in this study.
